C4 Therapeutics, Inc. — Director's Dealing 2021

Jan 26, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: C4 Therapeutics, Inc. (CCCC)
CIK: 0001662579
Period of Report: 2021-01-22

Reporting Person: Anderson Kenneth Carl (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-01-22	Common Stock	M	538	$2.11	Acquired	80914	Direct
2021-01-22	Common Stock	M	121	$2.11	Acquired	81035	Direct
2021-01-22	Common Stock	M	889	$4.98	Acquired	81924	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-01-22	Stock Option (Right to Buy)	$2.11	M	538	Disposed	2026-07-12	Common Stock (538)	Direct
2021-01-22	Stock Option (Right to Buy)	$2.11	M	121	Disposed	2026-07-12	Common Stock (121)	Direct
2021-01-22	Stock Option (Right to Buy)	$4.98	M	889	Disposed	2030-07-02	Common Stock (889)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	45038	Indirect
Common Stock	63543	Indirect
Common Stock	63543	Indirect
Common Stock	16939	Indirect
Common Stock	16939	Indirect

Footnotes

F1: Shares held by the Kenneth C. Anderson 2016 Grantor Retained Annuity Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

F2: Shares held the Cynthia E. Anderson 2016 Grantor Retained Annuity Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

F3: Shares held by the Kenneth C. Anderson 2015 Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

F4: Shares held by the Cynthia E. Anderson 2015 Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

F5: Represents underlying unexercised stock options that were granted on July 13, 2016. The terms of the original grant provide that 12.5% of this option vested and became exercisable on December 31, 2016, with the remainder vesting in 28 equal quarterly installments thereafter.

F6: The Form 3 filed on October 1, 2020 included an incorrect number of underlying securities in Table II, Column 3 (118).

F7: Represents underlying unexercised stock options that were granted on July 13, 2016. The terms of the original grant provide that 20% of this option vested and became exercisable on January 1, 2017, with the remainder vesting in 16 equal quarterly installments thereafter.

F8: This option shall vest and become exercisable in 12 equal quarterly installments, with the first installment vesting on October 1, 2020.